Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Nicholas C, Nicolaides"'
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0285161 (2023)
Subsets of tumor-produced cell surface and secreted proteins can bind to IgG1 type antibodies and suppress their immune-effector activities. As they affect antibody and complement-mediated immunity, we call these proteins humoral immuno-oncology (HIO
Externí odkaz:
https://doaj.org/article/7c49d45c87414ca3a70ea7ea76408466
Publikováno v:
Cancer Research. 83:1876-1876
Subsets of tumor-produced proteins, referred to as Humoral Immuno-Oncology (HIO) factors, can bind to IgG1 antibodies and suppress their immune-effector activities. Antibody-drug conjugates (ADCs) targeting tumor cell surface antigens can internalize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f403d700969912e438a58c3f358208d
https://doi.org/10.1158/1538-7445.am2023-1876
https://doi.org/10.1158/1538-7445.am2023-1876
Publikováno v:
Cancer Research. 83:5666-5666
Mesothelin (MSLN) is a cell surface protein over-expressed in a number of cancer types. Several antibody- and cellular-based MSLN targeting agents have been tested in clinical trials where their therapeutic efficacy has been moderate at best. Previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b47ccb05fb7ddfef3edf6b644e8df7f
https://doi.org/10.1158/1538-7445.am2023-5666
https://doi.org/10.1158/1538-7445.am2023-5666
Publikováno v:
Oncology Letters
Rituximab (RTX) is a CD20-targeting antibody that is the standard-of-care for patients with non-Hodgkin Lymphoma (NHL) cases. RTX's mechanism of action includes complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa7fa984d68a5b14029eef09f81a2665
http://europepmc.org/articles/PMC8607236
http://europepmc.org/articles/PMC8607236
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Novel technologies are being developed to improve patient therapy through the identification of targets and surrogate molecular signatures that can help direct appropriate treatment regimens for efficacy and drug safety. This is particularly the case
Externí odkaz:
https://doaj.org/article/592a8806bc78429e9eca723acfcf6e94
Publikováno v:
European Journal of Immunology. 48:1872-1882
C1q-engagement with IgG and IgM type antibodies is the initiating step of classical complement-mediated immunity. The tumor shed antigen CA125 has been reported to have immunosuppressive effects on host tumor responses as well as commercially approve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bbee1862e845d5233a91cb5c8073de1
https://doi.org/10.1002/eji.201847707
https://doi.org/10.1002/eji.201847707
Autor:
Erin N. Ross, J. Bradford Kline, Luigi Grasso, Nicholas C. Nicolaides, Charles Schweizer, Wenquan Wang, Elizabeth B. Somers, Shawn Fernando, Raffit Hassan
Publikováno v:
Cancer Biology & Therapy
The tumor-shed antigen CA125 has recently been found to bind certain monoclonal antibodies (mAbs) and suppress immune-effector mediated killing through perturbation of the Fc domain with CD16a and CD32a Fc-γ activating receptors on immune-effector c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc511129c7a66e107ec61f2e75bbc53
https://doi.org/10.1080/15384047.2018.1449614
https://doi.org/10.1080/15384047.2018.1449614
Autor:
Ryan M. Winters, Alexander W. MacFarlane, Nicholas C. Nicolaides, Sergei I. Grivennikov, Luigi Grasso, Jeffrey M. Farma, Prashanth Gokare, Abbas El-Sayed Abbas, Karen Kaputa, Kerry S. Campbell, Niklas Finnberg, Wafik S. El-Deiry, Avital Lev
Publikováno v:
Oncotarget
// Niklas K. Finnberg 1 , Prashanth Gokare 1 , Avital Lev 1 , Sergei I. Grivennikov 2 , Alexander W. MacFarlane IV 3 , Kerry S. Campbell 3 , Ryan M. Winters 4 , Karen Kaputa 4 , Jeffrey M. Farma 5 , Abbas El-Sayed Abbas 6 , Luigi Grasso 7 , Nicholas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5badd113a696cb1aa8ad0b46841608c1
http://europepmc.org/articles/PMC5620133
http://europepmc.org/articles/PMC5620133
Autor:
Jennifer M. McDonough, Luigi Grasso, Charles Schweizer, Elizabeth B. Somers, Wenquan Wang, Katherine Rybinski, Nicholas C. Nicolaides, Shawn Fernando, Rina P. Kennedy, Earl Albone, James Bradford Kline, Qimin Chao
Publikováno v:
Oncotarget
// James Bradford Kline 1 , Rina P. Kennedy 1 , Earl Albone 1 , Qimin Chao 1 , Shawn Fernando 1 , Jennifer M. McDonough 1 , Katherine Rybinski 1 , Wenquan Wang 1 , Elizabeth B. Somers 1 , Charles Schweizer 1 , Luigi Grasso 1 and Nicholas C. Nicolaide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b4f535625d52040d27848de949e185b
https://doi.org/10.18632/oncotarget.19090
https://doi.org/10.18632/oncotarget.19090
Autor:
Charles Schweizer, Nicholas C. Nicolaides, Rhonda Meredith, Wenquan Wang, Katie Bendas, Elizabeth B. Somers, Luigi Grasso, Mark Landers, Earl Albone, Jason Wustner, Daniel J. O'Shannessy, Susan C. Weil
Publikováno v:
Genomics. 109:251-257
Farletuzumab (FAR) is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha. A Ph3 trial in ovarian cancer patients treated with carboplatin/taxane plus FAR or placebo did not meet the primary statistical endpoint. Subgroup analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e902f6fb6b1203946eaf0187fe74c0c3
https://doi.org/10.1016/j.ygeno.2017.04.006
https://doi.org/10.1016/j.ygeno.2017.04.006